Ventyx Biosciences
Mar 11, 2021
Valo Health receives $110M Series B Cognito’s therapy slows Alzheimer’s disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio
Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
